TRIM65, TRIM65 variant 2, and its potential as a drug target or biomarker

Target Name: TRIM65

NCBI ID: G201292

TRIM65, TRIM65 variant 2, and its potential as a drug target or biomarker

TRIM65, a protein that belongs to the TRIM gene family, has been identified as a potential drug target or biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

The TRIM65 protein

TRIM65 is a 21-kDa protein that is expressed in various tissues and cells in the body. It is composed of 155 amino acid residues and has a calculated pI of 5.5. TRIM65 is involved in various cellular processes, including cell adhesion, migration, and invasion. It is also involved in the regulation of cell cycle progression and in the establishment of tissue repair processes.

TRIM65 variants

TRIM65 has several variants, including TRIM65 variant 1 and TRIM65 variant 2. TRIM65 variant 1 is a wild-type protein that has all the normal amino acid residues, whereas TRIM65 variant 2 is a mutant protein that has one amino acid substitution at position 64. This substitution results in a change in the protein's stability and localization to the endoplasmic reticulum (ER), where it can interact with various signaling molecules and contribute to the regulation of cellular processes.

Potential drug targets

TRIM65 is a protein that has been shown to interact with various signaling molecules, including TGF-β1, NF-kappa-B, and p53. These signaling pathways are involved in various cellular processes, including cell growth, differentiation, and stress response. Therefore, TRIM65 could be a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

TRIM65 has also been shown to play a role in the regulation of cellular processes that are important for cancer progression, such as the regulation of apoptosis (programmed cell death), cell invasion, and metastasis. Therefore, targeting TRIM65 with drugs that inhibit its activity could be an effective way to treat various cancers.

TRIM65 as a biomarker

TRIM65 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression has been shown to be elevated in various tissues and cells associated with these diseases, and its levels have been used as a diagnostic marker for some of these diseases.

For example, TRIM65 has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancers. It has also been shown to be elevated in the brains of patients with neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. In addition, TRIM65 has been shown to be elevated in the blood of patients with autoimmune disorders, such as rheumatoid arthritis and lupus.

TRIM65 has also been shown to be expressed in various tissues and cells that are involved in the regulation of autoimmune diseases, including the regulation of T cells and B cells. Therefore, its levels may be used as a biomarker for the diagnosis and monitoring of autoimmune disorders.

Conclusion

In conclusion, TRIM65 is a protein that has shown to be involved in various cellular processes that are important for cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function make it an attractive target for researchers to study and develop new treatments. As a potential drug target or biomarker, TRIM65 has the potential to contribute to the treatment of a wide range of diseases. Further research is needed to fully understand its role in these diseases and to develop effective treatments.

Protein Name: Tripartite Motif Containing 65

Functions: E3 ubiquitin ligase that plays a role in several processes including innate immnity, autophagy or inflammation (PubMed:28594402, PubMed:34512673). Negatively regulates miRNAs by modulating the ubiquitination and stability of TNRC6A, a protein involved in RNA-mediated gene silencing by both micro-RNAs (miRNAs) and short interfering RNAs (PubMed:24778252). This ubiquitination results in the suppressed expression of miR-138-5p leading to increased autophagy (PubMed:31160576). Upon enteroviral infection, promotes 'Lys-63'-mediated ubiquitination activation of IFIH1/MDA5 leading to innate signaling cascade (PubMed:28594402). Mechanistically, selectively recognizes MDA5 filaments that occur on dsRNAs (PubMed:33373584). Plays also a role in limitation of inflammation through different mechanisms. First, promotes 'Lys-48'-mediated ubiquitination of VCAM1 leading to its degradation and limitation of LPS-induced lung inflammation (PubMed:31310649). In addition, negatively regulates inflammasome activation by promoting 'lys48'-linked ubiquitination of NLRP3 which is critical for the inhibition of NLRP3 inflammasome activation in resting macrophages (PubMed:34512673)

More Common Targets